Trade Blueprint Medicines Corporation - BPMC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.72 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 85.39 |
| Open | 83.51 |
| 1-Year Change | -9.51% |
| Day's Range | 83.51 - 87.35 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 85.39 | 0.73 | 0.86% | 84.66 | 86.44 | 84.14 |
| Apr 23, 2025 | 85.31 | 0.24 | 0.28% | 85.07 | 86.51 | 84.22 |
| Apr 22, 2025 | 82.87 | 1.19 | 1.46% | 81.68 | 85.20 | 81.68 |
| Apr 21, 2025 | 83.61 | -0.01 | -0.01% | 83.62 | 85.91 | 82.87 |
| Apr 17, 2025 | 84.63 | 4.61 | 5.76% | 80.02 | 84.77 | 80.02 |
| Apr 16, 2025 | 81.48 | 1.58 | 1.98% | 79.90 | 82.08 | 78.42 |
| Apr 15, 2025 | 80.85 | -0.88 | -1.08% | 81.73 | 83.24 | 79.48 |
| Apr 14, 2025 | 82.12 | 1.49 | 1.85% | 80.63 | 83.21 | 79.15 |
| Apr 11, 2025 | 80.27 | 5.20 | 6.93% | 75.07 | 81.07 | 75.07 |
| Apr 10, 2025 | 79.77 | 1.82 | 2.33% | 77.95 | 81.48 | 76.36 |
| Apr 9, 2025 | 81.51 | 4.28 | 5.54% | 77.23 | 83.09 | 72.72 |
| Apr 8, 2025 | 79.23 | -1.73 | -2.14% | 80.96 | 84.11 | 77.01 |
| Apr 7, 2025 | 79.73 | 0.78 | 0.99% | 78.95 | 83.36 | 76.02 |
| Apr 4, 2025 | 81.61 | -3.29 | -3.88% | 84.90 | 85.67 | 79.92 |
| Apr 3, 2025 | 87.01 | 1.07 | 1.25% | 85.94 | 89.05 | 85.85 |
| Apr 2, 2025 | 89.92 | 5.21 | 6.15% | 84.71 | 90.20 | 84.71 |
| Apr 1, 2025 | 85.48 | -0.57 | -0.66% | 86.05 | 88.36 | 84.47 |
| Mar 31, 2025 | 87.94 | 1.50 | 1.74% | 86.44 | 88.56 | 84.61 |
| Mar 28, 2025 | 88.61 | -0.41 | -0.46% | 89.02 | 89.33 | 87.25 |
| Mar 27, 2025 | 89.14 | -0.35 | -0.39% | 89.49 | 92.16 | 89.14 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Blueprint Medicines Corporation Company profile
About Blueprint Medicines Corp
Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com